Post Autologous Bone Marrow Transplant Associated With a Resultant Mixed Polyclonal/Monoclonal Hyper-IgG3.
Lauren FillMarija J RowaneKelsey GravenNeha SananShan Shan WuRobert W HostofferPublished in: Allergy & rhinology (Providence, R.I.) (2020)
There have been few studies illustrating the post immunological phenotype of patients receiving autologous bone marrow transplant (ABMT) for the treatment of diffuse large B-cell lymphoma. High-dose chemotherapy and autologous bone marrow transplantation have been shown to be the only potential curative treatment modalities for B-cell lymphoma. Autologous bone marrow transplantation, although widely utilized in patients with non-Hodgkin lymphoma recurrence, does have an association with immunologic side effects, although serologic changes where rarely reported unless accompanied by recurrent infections. We report the first case of a 62-year-old female patient who experienced recurrent infections, namely, sinusitis and pneumonia, after receiving an ABMT with subsequent hyper-IgG3 phenotype.
Keyphrases
- bone marrow
- diffuse large b cell lymphoma
- mesenchymal stem cells
- high dose
- cell therapy
- epstein barr virus
- low dose
- squamous cell carcinoma
- stem cells
- radiation therapy
- stem cell transplantation
- risk assessment
- climate change
- sars cov
- intensive care unit
- combination therapy
- multiple myeloma
- smoking cessation
- free survival
- extracorporeal membrane oxygenation